These findings thus suggest that LINC00326 targets the miR-657/DKK2 pathway to control NSCLC development, while miR-657 acts through the targeting of DKK2, and that disruption of this process leads to tumor development mediated by Wnt/β-catenin signaling (Fig. 9). Here, LINC00326 is linked to non-small cell lung carcinoma.